The following information appeared on, reuters.com
On January 11, 2022, CMS announced that it will limit coverage of Biogen’s costly Alzheimer’s disease drug, Aduhelm, to patients enrolled in approved randomized clinical trials. “While there may be the potential for promise with this treatment, there’s also the potential for serious harm to patients,” CMS Chief Medical Officer Lee Fleisher said, though Biogen said the decision “will exclude almost all patients who may benefit.”
